Mersana Therapeutics, Inc. (MRSN) financial statements (2022 and earlier)

Company profile

Business Address 840 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments177,947255,09499,79070,131114,734
Cash and cash equivalents177,947255,09462,35159,63426,591
Short-term investments  37,43910,49788,143
Receivables   459784
Other undisclosed current assets10,9513,4861,5363,7152,025
Total current assets:188,898258,580101,32674,305117,543
Noncurrent Assets
Operating lease, right-of-use asset12,88910,9362,598
Property, plant and equipment1,9681,7302,1642,6942,319
Long-term investments and receivables    10,482
Long-term investments    10,482
Other noncurrent assets2,3562,1531,4531,503371
Total noncurrent assets:17,21314,8196,2154,19713,172
TOTAL ASSETS:206,111273,399107,54178,502130,715
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities41,03724,48616,28223,10210,014
Accounts payable12,3218,3407,29610,7273,070
Accrued liabilities28,71616,1468,98612,3756,944
Deferred revenue3,9443,9874,815
Debt239932,886  
Deferred rent credit   127
Deferred revenue and credits21,867
Contract with customer, liability46,196
Other liabilities2399387  
Other undisclosed current liabilities2,0641,344   
Total current liabilities:47,52330,00324,07069,42531,881
Noncurrent Liabilities
Long-term debt and lease obligation35,87315,1354,878  
Long-term debt, excluding current maturities24,6264,9774,201  
Operating lease, liability11,24710,158677
Liabilities, other than long-term debt97417427528228,840
Deferred revenue and credits28,840
Deferred rent credit   282
Other liabilities974174275  
Total noncurrent liabilities:36,84715,3095,15328228,840
Total liabilities:84,37045,31229,22369,70760,721
Stockholders' equity
Stockholders' equity attributable to parent121,741228,08778,3188,79569,994
Common stock77533
Additional paid in capital572,213508,499270,662172,966168,018
Accumulated other comprehensive income (loss)  25(8)(149)
Accumulated deficit(450,479)(280,419)(192,374)(164,166)(97,878)
Total stockholders' equity:121,741228,08778,3188,79569,994
TOTAL LIABILITIES AND EQUITY:206,111273,399107,54178,502130,715

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues4382842,12310,59417,545
Gross profit:4382842,12310,59417,545
Operating expenses(168,901)(88,938)(72,323)(76,249)(57,162)
Operating loss:(168,858)(88,110)(30,200)(65,655)(39,617)
Nonoperating income (expense)(1,202)651,9921,398910
Investment income, nonoperating654242,226  
Interest and debt expense(1,267)(359)(234)  
Loss before gain (loss) on sale of properties:(171,327)(88,404)(28,442)(64,257)(38,707)
Other undisclosed net income1,267359234  
Net loss available to common stockholders, diluted:(170,060)(88,045)(28,208)(64,257)(38,707)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(170,060)(88,045)(28,208)(64,257)(38,707)
Other comprehensive income (loss) (25)33141(149)
Comprehensive loss, net of tax, attributable to parent:(170,060)(88,070)(28,175)(64,116)(38,856)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: